The Clinical Value of Bevacizumab Combined with Targeted Drug Therapy for Non-small Cell Lung Cancer
Objective To analyze the clinical value of bevacizumab combine with targeted therapy in patients with non-small cell lung cancer.Methods A total of 98 patients with non-small cell lung cancer admitted to Beicheng Hos-pital of Juye County from February 2022 to January 2023 were conveniently selected as the research objects.They were divided into control group and study group by double-blind method,with 49 cases in each group.The patients in the control group were treated with targeted therapy,and the patients in the study group were treated with bevaci-zumab on this basis.The levels of tumor markers,clinical efficacy,adverse reactions and survival indicators were com-pared between the two groups.Results Before treatment,there was no significant difference in the levels of cancer anti-gen 125(CA125),carcinoembryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1)between the two groups(all P＞0.05).After treatment,the levels of CA125,CEA and CYFRA21-1 in the study group were lower than those in the control group,the differences were statistically significant(all P＜0.05).The clinical effective rate(95.92%)and clinical remission rate(77.55%)in the study group were higher than those in the control group(79.59%,48.98%),and the differences were statistically significant(χ2=6.078,8.606,both P＜0.05).The total incidence of ad-verse reactions in the study group(6.12%)was lower than that in the control group(22.45%),and the difference was statistically significant(P＜0.05).The survival rate of patients in the study group at half year follow-up(100.00%)and 1 year follow-up(87.76%)were higher than those in the control group(91.84%,71.11%),and the differences were sta-tistically significant(both P＜0.05).Conclusion The combination of bevacizumab and targeted drugs can improve the clinical effective rate and clinical remission rate,reduce the level of tumor markers,maintain the long-term survival rate at a high level,prevent and control safety incidents,and improve the prognosis of non-small cell lung cancer.
NETL
NSTL
万方数据
